ITIF Logo
ITIF Search
Center for Life Sciences Innovation

Center for Life Sciences Innovation

ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play. The Center’s mission is to study and advance the many technology, economic, and policy factors underpinning successful life sciences innovation—from how new technologies like artificial intelligence, genomics, and gene editing are powering the next generation of biomedical innovation to the economics of life sciences innovation, including the role of IP and incentives therein; international competitiveness in life sciences innovation; and foremost the optimal set of public policies, at home and abroad, to spur greater levels of much-needed biopharmaceutical innovation.

Featured Publications

The Relationship Between Biopharma R&D Investment and Expected Returns: Improving Evidence to Inform Policy

The Relationship Between Biopharma R&D Investment and Expected Returns: Improving Evidence to Inform Policy

Better evidence is needed to evaluate the impact of policy changes on new drug development. Greater availability of government data should support more rigorous evaluations to inform evidence-based policymaking.

LATAM Health Champions, 2024

LATAM Health Champions, 2024

Innovation plays a critical role in improving public health and in overcoming global health challenges. The call for LATAM Health Champions, which ran from February 5 to March 5, 2024, received more than 60 applications proposing innovative health solutions to a wide range of health challenges. Here, the top 20 are highlighted.

Not Again: Why the United States Can’t Afford to Lose Its Biopharma Industry

Not Again: Why the United States Can’t Afford to Lose Its Biopharma Industry

America’s leadership in advanced-technology industries can never be taken for granted, as evidenced by its losses in telecommunications equipment, semiconductors, televisions, solar panels, and chemicals. Policymakers must recognize what went wrong in those cases to avoid a similar industrial decline in the biopharmaceutical industry.

How Skeptics Misconstrue the Link Between Drug Prices and Innovation

How Skeptics Misconstrue the Link Between Drug Prices and Innovation

A recent article in the British Medical Journal contends “high drug prices” are neither necessary nor justified to sustain biopharmaceutical innovation. But it misrepresents and misinterprets the facts, highlighting how faulty the rationale is for drug price controls.

Preserving US Biopharma Leadership: Why Small, Research-Intensive Firms Matter in the US Innovation Ecosystem

Preserving US Biopharma Leadership: Why Small, Research-Intensive Firms Matter in the US Innovation Ecosystem

America is home to 85 percent of the world’s small, research-intensive biopharma firms. These start-ups are critical to drug development and U.S. competitiveness. Congress should make targeted changes to tax policy to incentivize them and maintain U.S. biopharma leadership.

More Publications

Events

March 5, 2024

Preserving U.S. Leadership in Biopharmaceutical Innovation

Watch now for an expert panel discussion surrounding the ITIF report examining why the United States lost its lead in other advanced technology industries, and how policymakers can avoid repeating the same mistakes in the biopharmaceutical sector.

April 4, 2023

Lessons From the Rise and Fall of Japan’s Life-Sciences Innovation Ecosystem

Tune in for an expert panel discussion examining where Japan faltered in this sector, what it must do to restore its life-sciences innovation leadership and competitiveness, why that would be in the best interests of both Japan and the United States—and what America must do to avoid following in Japan’s footsteps.

March 24, 2023

Preserving a Virtuous Cycle: The Economics of Biopharmaceutical Innovation

Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation.

March 29, 2022

How Using March-in Rights Would Threaten America’s Research Universities

ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.

April 29, 2021

How Intellectual Property Has Played a Pivotal Role in the Global COVID-19 Response

ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.

More Events

Staff

Sandra Barbosu
Sandra Barbosu

Senior Policy Manager

Read Bio
Stephen Ezell
Stephen Ezell

Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation

Information Technology and Innovation Foundation

Read Bio

Advisors

Bill Andresen
Bill Andresen

Associate Vice President for Federal Affairs

University of Pennsylvania

Read Bio
David Beier
David Beier

Managing Director

Bay City Capital

Read Bio
Andrei Iancu
Andrei Iancu

Partner

Irell & Manella, LLP

Read Bio
Frank R. Lichtenberg
Frank R. Lichtenberg

Cain Brothers & Company Professor of Healthcare Management in the Faculty of Business

Columbia University Graduate School of Business

Read Bio
Catherine Marinac
Catherine Marinac

Assistant Professor of Medicine

Harvard Medical School

Read Bio
Gary Puckrein
Gary Puckrein

Founding President and CEO

National Minority Quality Forum

Read Bio

More From the Center

May 13, 2024|Blogs

Advancing Biomedical Innovation With Policies Supporting Privacy-Enhancing Technologies

By improving privacy protection and facilitating secure collaborative research, privacy-enhancing technology could complement data-sharing policies and enable analysis of sensitive medical data and support biomedical innovation.

February 6, 2024|Testimonies & Filings

Comments to the NIST Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

America’s innovation system is fragile, and its leadership in advanced technology industries is never guaranteed or assured. The United States has taken—only to sacrifice—its lead in a wide-range of advanced technology industries, often in part because of significant policy lapses. It’s no time for additional unforced errors.

January 31, 2024|Testimonies & Filings

Comments to the U.S. Department of Health and Human Services Regarding the WHO Pandemic Preparedness Agreement

The United States should not endorse an IPR waiver in the WHO Pandemic Preparedness Agreement. It would not increase the number of vaccines or therapeutics, or the global supply that might be needed to address a future global pandemic.

December 11, 2023|Blogs

Biden’s Assertion of Excessive Biopharma Industry Concentration Is a Flawed Rationale for a Flawed Policy

The administration is flat wrong that America’s biopharmaceutical industry is excessively concentrated. It’s also flat wrong that U.S. drug prices are rising out of control.

November 13, 2023|Testimonies & Filings

Comments to the European Commission Regarding the EU General Pharmaceuticals Legislation

Changes proposed in the EU General Pharmaceutical Legislation would double down on policies that hinder, not enable, EU life-sciences innovation potential, while forsaking other avenues that could more effectively enhance access without compromising innovation.

August 18, 2023|Testimonies & Filings

Comments to the National Institutes of Health on “Maximizing NIH’s Levers to Catalyze Technology Transfer”

The technology-transfer regime the United States has implemented over the past four decades, largely as enabled through the Bayh-Dole Act, has been tremendously effective in stimulating innovation, especially in the life sciences. While all such processes should be continuously streamlined or tweaked where improvement is possible, the current system does not need serious modification or reform.

July 17, 2023|Reports & Briefings

The Hidden Toll of Drug Price Controls: Fewer New Treatments and Higher Medical Costs for the World

When nations implement pharmaceutical price controls, they reduce pharmaceutical revenues, which then reduces investments in further R&D, limiting future generations’ access to new novel treatments needed to fight diseases such as cancer, Alzheimer’s, heart disease, and diabetes.

See All

Back to Top